ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device

Rhea-AI Summary

ProSomnus (NASDAQ:OSAP) announced on April 13, 2026 that the FDA granted Class II 510(k) clearance (K252765) for the RPMO₂ OSA Device. The device is described as the first theragnostic oral appliance combining precision therapy with multi-night SpO₂ and pulse monitoring, enabling continuous physiologic data for Smart Sleep Medicine.

The clearance covers product codes DQA, LQZ, LRK, PLC, and OUG and affirms the device meets FDA standards for measuring oxygen saturation and pulse rate, supporting clinician-led titration and longitudinal treatment monitoring.

Positive

• FDA Class II 510(k) clearance received on April 13, 2026 (K252765)
• First theragnostic oral appliance combining therapy and multi-night physiologic monitoring
• Continuous SpO₂ and pulse measurement built into one device for longitudinal patient data
• Supports data-driven titration and multi-night adherence tracking to improve clinical management

Negative

• None.

Market Context

This announcement highlights FDA Class II 510(k) clearance for ProSomnus’s RPMO2 device, which integ...

Analysis

This announcement highlights FDA Class II 510(k) clearance for ProSomnus’s RPMO2 device, which integrates precision oral appliance therapy with continuous SpO₂ and pulse rate monitoring. The news underlines a shift toward connected, data-driven OSA care and positions RPMO2 as a theragnostic tool in sleep medicine. With no recent historical news reactions available, investors would likely focus on subsequent disclosures around clinical utilization, payer coverage, and real-world adoption to gauge long-term impact.

Key Figures

Regulatory pathway: Class II 510(k) clearance

1 metrics

Regulatory pathway Class II 510(k) clearance FDA clearance for RPMO2 OSA Device (K252765)

Key Terms

510(k) clearance, obstructive sleep apnea, SpO₂, oximetry, +3 more

7 terms

510(k) clearance regulatory

"FDA has granted Class II 510(k) clearance for its RPMO₂ OSA Device"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

obstructive sleep apnea medical

"the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

SpO₂ medical

"safety and effectiveness in measuring oxygen saturation (SpO₂) and pulse rate"

SpO₂ is the percentage of oxygen carried in the blood as measured noninvasively by a pulse oximeter placed on a finger or earlobe, like a quick reading of how full a tank is. Investors track SpO₂ because it is a simple clinical indicator of respiratory and overall health that drives demand for medical devices, home-monitoring products, treatments, and hospital services, and it can influence regulatory outcomes and reimbursement decisions.

oximetry medical

"a miniature, highly accurate, comfortable oximeter capable of real-world performance"

Oximetry is the noninvasive measurement of how much oxygen is carried in the blood, typically done with a small sensor clipped to a fingertip or earlobe — like a fuel gauge showing how full the body’s oxygen tank is. Investors care because oximetry readings are often used as clinical endpoints, product features, or regulatory evidence; changes in device accuracy, reimbursement, or clinical use can affect demand, approvals, and a medical company’s revenue and valuation.

buccal mucosa medical

"application of oximetry to the buccal mucosa bypasses concerns of oximetry accuracy"

The buccal mucosa is the soft, moist lining on the inside of the cheeks and lips that serves as an accessible surface inside the mouth. It matters to investors because it is often used as a noninvasive site for delivering drugs, taking diagnostic samples, or harvesting tissue for grafts, which can simplify clinical trials, lower procedure costs and patient risk, and influence regulatory review and market adoption of medical products.

hypoxic burden medical

"Hypoxic burden is the underpinning of many OSA-related diseases"

Hypoxic burden is a measure of how much and how long a person's blood oxygen levels fall below normal, combining the depth and duration of low-oxygen events into a single score. Investors care because it is used to evaluate the severity of respiratory and sleep disorders, guide treatment decisions, and influence demand for medical devices, drugs and diagnostics — like knowing how often and how badly a car runs low on fuel, which affects maintenance and replacement needs.

oral appliance therapy medical

"Oral Appliance Therapy is integral to the treatment of Obstructive Sleep Apnea"

A treatment that uses a custom-fitted device worn in the mouth—similar to a dental retainer—to reposition the jaw or tongue and keep the upper airway open during sleep, reducing snoring and mild-to-moderate obstructive sleep apnea. It matters to investors because demand, reimbursement rules, clinical effectiveness and regulatory clearance determine market size, recurring revenue from fittings and replacements, and competitive positioning in the sleep-disorder and dental-device markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO₂ OSA Device is the first theragnostic device for sleep medicine, incorporating both precision oral appliance therapy and multi-night physiologic monitoring in one device.

This clearance affirms that the ProSomnus RPMO₂ OSA Device meets the FDA’s standards for safety and effectiveness in measuring oxygen saturation (SpO₂) and pulse rate, positioning the device as a cornerstone of a new Smart Sleep Medicine era characterized by connected, patient centric, evidence-driven OSA care.

Commentary
“The FDA’s clearance of the RPMO₂ OSA Device marks a significant milestone for sleep medicine,” stated Len Liptak, Chief Executive Officer of ProSomnus. “By integrating safe, accurate, continuous physiologic measurement into our precision oral appliance platform, we are enabling Smart Sleep Medicine—a connected, data driven model that helps clinicians manage sleep apnea as the personal, individualized and chronic disease it truly is.”

“The RPMO₂ OSA Device represents years of innovation in engineering, human centric design, and rigorous scientific validation. We set out to create a miniature, highly accurate, comfortable oximeter capable of real-world performance. FDA clearance confirms that we achieved this goal and opens the door to continuous insight into patient physiology,” commented Sung Kim, ProSomnus Chief Technology Officer.

“Dentists play a vital role in screening and treating Obstructive Sleep Apnea (OSA). The ProSomnus RPMO₂ OSA Device gives dental providers a powerful new tool—real world data that shows how patients are responding night after night. This enables proactive, personalized care, enhanced communication with patients and physicians, and improved outcomes, commented Mark Murphy, DDS, D.ABDSM, FAASM, ProSomnus Dental Sleep Medicine Director.

“The ProSomnus RPMO₂ OSA Device stands to elevate the practice of sleep medicine by simplifying device titration by allowing for the use of robust, objective SpO₂ data to guide device titration where previously subjective patient feedback has been used,” noted Erin Mosca, PhD, ProSomnus Director of Scientific and Medical Affairs.

“Oral Appliance Therapy is integral to the treatment of Obstructive Sleep Apnea, and oximetry is integral to its diagnosis and follow up. The ProSomnus RPMO₂ OSA Device now offers clinicians the ability to continuously and easily monitor treatment without employing additional diagnostic tools. The implications for managing such a large number of patients are self-evident,” commented Adrian Williams, MD, PhD.

“For the first time, clinicians can pair precision oral appliance therapy with continuous, longitudinal physiologic monitoring. This supports data driven treatment adjustments, mitigates limitations of single night testing, and positions sleep apnea care alongside modern chronic disease management paradigms,” noted Edward Sall, MD, DDS, ProSomnus Medical Director.

“Oral appliances play an increasing role in the therapeutic armamentarium for sleep apnea. The RPMO₂ OSA Device provides the potential to more rapidly titrate patients on oral appliance therapy to an effective setting. The ability to monitor oximetry and adherence over multiple nights should allow for more accurate assessments of treatment efficaciousness. In addition, the application of oximetry to the buccal mucosa bypasses concerns of oximetry accuracy on pigmented skin and so should help reduce existing racial disparities in sleep apnea care. I am excited about the potential that RPMO₂ has to improve the care of my patients with sleep apnea,” stated Sanjay V. Patel, MD.

“Efficacy of and adherence to interventions in chronic illness are key pillars of disease control and improved outcomes, and OSA is no exception. Hypoxic burden is the underpinning of many OSA-related diseases. Continuous SpO₂ monitoring with ProSomnus RPMO₂ uniquely provide a pathophysiologically derived efficacy measure. RPMO₂ goes one step forward and provides a measure of adherence that was not available previously. The above makes RPMO₂ an important paradigm changing technology in a major intervention for management of OSA,” commented Amir Sharafkhaneh, MD, PhD.

“From preliminary research we have been doing in our clinics, we have found the ProSomnus RPMO₂ OSA Device to be very reliable when comparing the physiologic data to that proffered by robust sleep studies, giving us confidence when discussing this new technology with both patients and our referral sources. This not only allows us to monitor treatment success nightly for titration purposes, but we see better compliance as patients love to see how their previous day’s activities influenced the quality of their sleep,” stated Kent Smith, D.ABDSM, FAASM.

“Access to nightly physiologic data with the ProSomnus RPMO₂ OSA Device has fundamentally changed how we manage OAT for OSA patients. Instead of relying on snapshot testing or symptoms alone, we can track trends over time, make more precise titration decisions, reduce unnecessary testing, and identify issues earlier—ultimately improving outcomes, patient adherence, and confidence in both the therapy and our clinical recommendations,” commented Stacey Layman, DDS, D.ABDSM, D.ABSA.

“The ProSomnus RPMO₂ OSA Device has transformed how I evaluate Oral Appliance Therapy. Multi-night, medically verified data reveals night-to-night variability that one- or two-night titration studies simply miss, enabling truly patient-specific, data-driven treatment decisions. Physician colleagues are consistently impressed by the rigor of the validation, the quality of the data, and the high patient adherence—and prefer their patients treated with therapy supported by this level of objective monitoring,” noted Michael J. Murray, DDS.

About the ProSomnus RPMO₂ OSA Device
The ProSomnus RPMO₂ OSA Device is the first theragnostic device for sleep medicine, featuring a wholly embedded oximeter for safe, accurate and economical treatment and multi-night monitoring of OSA. The oximeter is encapsulated in an overlay of the maxillary dentition and uses the mucosa of the buccal vestibule behind the upper lip as the reflective tissue. Data are transmitted to a secure provider portal via patient smartphone app.

Validated Accuracy and Safety
The RPMO₂ OSA Device’s FDA clearance is supported by a rigorous, gold standard validation study conducted at the University of Calgary and published by Snow et al. (2025). The study evaluated the accuracy of the intraoral buccal mucosal oximeter against arterial oxyhemoglobin saturation measured using CO oximetry, the clinical gold standard for oxygen saturation measurement.

Comprehensive Controlled Desaturation Study
The study enrolled 12 healthy adults, consistent with ISO 80601 2 61 requirements, and included participants with a spectrum of skin pigmentation.

Participants underwent six precisely controlled hypoxic plateaus, spanning ~97% to ~72% SaO2. Analysis of accuracy was performed on 325 SaO₂/SpO₂ data pairs and 346 pulse rate/ECG data pairs.

Oxygen Saturation Accuracy
The RPMO₂ OSA Device demonstrated strong clinical accuracy across the full range of 70-100% SaO₂:

• Accuracy Root Mean Square (ARMS) for SpO₂: 2.94%
• Correlation between SpO2 and SaO₂: r = 0.95
• Bland-Altman: mean bias of 0.72, upper and lower 95% limits of agreement of 6.31 and -4.86, respectively
• Consistent accuracy across entire range of SaO2 tested

Importantly, the study reported no systematic bias across skin pigmentation groups. The buccal mucosa, which is thought to contain less melanin than the epidermis, may reduce the overestimation of oxygen saturation seen in conventional fingertip devices that measure through melanin-rich tissue.

Pulse Rate Accuracy
The RPMO₂ OSA Device also demonstrated excellent pulse rate measurement performance:

• ARMS: 2.08 beats per minute
• Correlation between pulse rate and ECG: r = 0.99
• Bland-Altman: mean bias of 0.30, upper and lower 95% limits of agreement of 4.34 and -3.73, respectively
  

Mitigation of Known Oximetry Confounders
The innovative intraoral design of the RPMO₂ OSA Device addresses several long recognized limitations of conventional pulse oximeters:

• Motion artifact reduction: Stable placement high in the buccal vestibule minimizes motion-induced noise.
• High perfusion site: The buccal mucosa is richly vascularized, supporting high quality photoplethysmography.
• Thermal stability: The temperature-stable intraoral environment avoids temperature dependent perfusion variability.
• Intrinsic light shielding: The vestibular location protects the sensor from ambient light interference.
• Low melanin interference: Measurement through mucosa may reduce racial bias inherent in skin based oximetry.
  

Collectively, these attributes support the RPMO₂ OSA Device’s suitability for accurate, nightly physiologic monitoring in real world settings.

Enabling Smart Sleep Medicine™
The FDA clearance of the RPMO₂ OSA Device unlocks Smart Sleep Medicine, ProSomnus’s next generation, connected care model for managing OSA as a chronic disease. The RPMO₂ OSA Device enables:

• Longitudinal physiologic monitoring across nights and treatment stages
• Evidence based, connected care workflows including remote physiologic monitoring (RPM)
• Real world insights enabling personalization of precision oral appliance therapy
• Improved patient engagement and outcomes through continuous, comfortable monitoring

About ProSomnus Sleep Technologies
ProSomnus is the pioneer and global leader in Smart Sleep Medicine, providing a technology-enabled, non-CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA). A serious medical disease affecting over 1 billion people worldwide, OSA is linked to life-threatening comorbidities including heart failure, stroke, and type 2 diabetes.

By integrating precision-engineered intraoral medical devices with advanced remote patient monitoring (RPM) and data-driven diagnostics, ProSomnus is redefining the standard of care. Our platform is designed to provide continuous, nightly clinical insights that ensure superior adherence and validated patient outcomes. Non-invasive and patient-preferred, ProSomnus devices have demonstrated exceptional efficacy and safety across a rigorous and growing body of clinical evidence. ProSomnus precision devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing over 200 million covered lives globally. To learn more about the future of sleep health, visit www.ProSomnus.com.

Media Contact
Heather Whalen
HWhalen@ProSomnus.com

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/333d9b0e-92b8-4e8b-ab32-6689f4113578

https://www.globenewswire.com/NewsRoom/AttachmentNg/ee5d552e-1f94-4ff6-a882-da6005819492

FAQ

What did ProSomnus announce about FDA clearance for RPMO2 (OSAP) on April 13, 2026?

ProSomnus announced FDA Class II 510(k) clearance for the RPMO₂ OSA Device on April 13, 2026. According to the company, clearance (K252765) covers SpO₂ and pulse measurement under product codes DQA, LQZ, LRK, PLC, and OUG.

How does the RPMO2 OSA Device change treatment monitoring for dental sleep medicine (OSAP)?

RPMO₂ pairs oral appliance therapy with continuous multi-night physiologic monitoring for OSA. According to the company, clinicians can use objective SpO₂ and pulse data night after night to guide titration and assess treatment efficacy and adherence.

What clinical measurements does the ProSomnus RPMO2 (OSAP) provide for patients with OSA?

The device measures continuous oxygen saturation (SpO₂) and pulse rate across multiple nights. According to the company, integrated monitoring yields longitudinal physiologic data to reduce reliance on single-night tests and improve individualized care.

What investor implications does FDA 510(k) clearance of RPMO2 have for ProSomnus (OSAP)?

Clearance may broaden market access for a differentiated, monitored oral appliance offering. According to the company, FDA 510(k) status validates the device's safety and effectiveness for SpO₂ and pulse measurement, supporting commercial adoption by dental and sleep clinicians.

What is the FDA 510(k) identifier and product scope for ProSomnus RPMO2 (OSAP)?

The RPMO₂ OSA Device clearance is recorded under K252765 and covers product codes DQA, LQZ, LRK, PLC, and OUG. According to the company, the clearance affirms measurement of oxygen saturation and pulse rate for clinical use.